Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Valo Health Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so each recorded action has its own examination context.
RAO, SAVITHA M is the busiest examiner, with 1 pending action. Counsel can use a common biotechnology claim framework where appropriate, but should tailor each response to its assigned examiner, art unit, and cited technical issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| ESPERON, NATHAN GREGORY | 1 | 41.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706756 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | RAO, SAVITHA M | — |
| 18500552 | Artificial Skeletal Muscle Tissue | ESPERON, NATHAN GREGORY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706756 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | RAO, SAVITHA M | — |
| 18500552 | Artificial Skeletal Muscle Tissue | ESPERON, NATHAN GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706756 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | RAO, SAVITHA M | 1691 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18500552 | Artificial Skeletal Muscle Tissue | ESPERON, NATHAN GREGORY | 1799 | §103§112Other | Final Rejection | — | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialValo Health Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Savitha M Rao has the most, with 1 of Valo Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
